Flora Peyvandi / X
May 28, 2025, 12:48
Flora Peyvandi Shares New AVA-PED-301 Study on Avatrombopag in Pediatric ITP
Flora Peyvandi, recently posted on X:
“Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study.”
Read more about it in The Lancet.
Discover more in Hemostasis Today.
-
Jul 16, 2026, 00:20Mettine Bos: Reflecting on a Fantastic ISTH 2026 in Paris with Team Leiden
-
Jul 16, 2026, 00:19Pierre Grès: Proud to Present My PhD Research at ISTH 2026
-
Jul 16, 2026, 00:19Francis Couturaud: Leela Breton Presents Promising PE Research at ISTH 2026
-
Jul 16, 2026, 00:18Alisa Wolberg: An Honor to Present the Gualtiero Palareti Memorial Plenary Lecture at ISTH 2026
-
Jul 16, 2026, 00:17Edward Lee Carter: What ISTH 2026 Tells Us About the Next Era of Thrombosis Care
-
Jul 16, 2026, 00:17Marc Carrier: Celebrating 25 Years of the Adult Thrombosis Fellowship Program at ISTH 2026
-
Jul 16, 2026, 00:16Nikolaos Kotsiou: The Privilege of Presenting Our Clinic’s Newest Findings at My 1st ISTH 2026
-
Jul 16, 2026, 00:14Empowering the Next Generation of Bleeding Disorders Leaders – WFH
-
Jul 16, 2026, 00:13Wolfgang Miesbach: VOYAGER1 Highlights the Potential of Oral Inno8 at ISTH 2026